Personalis (NASDAQ:PSNL) CFO Sells $480,400.00 in Stock

Personalis, Inc. (NASDAQ:PSNL) CFO Aaron Tachibana sold 40,000 shares of the business’s stock in a transaction dated Thursday, June 4th. The stock was sold at an average price of $12.01, for a total transaction of $480,400.00. Following the sale, the chief financial officer owned 198,833 shares in the company, valued at $2,387,984.33. This trade represents a 16.75% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Aaron Tachibana also recently made the following trade(s):

• On Friday, May 29th, Aaron Tachibana sold 38,799 shares of Personalis stock. The stock was sold at an average price of $11.58, for a total transaction of $449,292.42.

Personalis Stock Performance

Shares of PSNL stock traded down $1.35 during midday trading on Friday, reaching $10.75. 4,145,011 shares of the company were exchanged, compared to its average volume of 2,893,865. Personalis, Inc. has a 12 month low of $3.84 and a 12 month high of $12.53. The company has a market cap of $1.13 billion, a P/E ratio of -10.54 and a beta of 2.28. The company’s 50 day moving average price is $7.23 and its two-hundred day moving average price is $8.21.

Personalis (NASDAQ:PSNL) last released its quarterly earnings results on Thursday, May 7th. The company reported ($0.29) EPS for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.06). Personalis had a negative return on equity of 43.52% and a negative net margin of 148.11%.The company had revenue of $15.47 million for the quarter, compared to the consensus estimate of $14.49 million. As a group, sell-side analysts predict that Personalis, Inc. will post -1.06 earnings per share for the current year.

Hedge Funds Weigh In On Personalis

A number of hedge funds and other institutional investors have recently modified their holdings of PSNL. Caitong International Asset Management Co. Ltd raised its holdings in shares of Personalis by 76.1% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 3,423 shares of the company’s stock valued at $27,000 after acquiring an additional 1,479 shares during the period. Legal & General Group Plc acquired a new stake in shares of Personalis during the second quarter valued at approximately $30,000. International Assets Investment Management LLC acquired a new stake in shares of Personalis during the fourth quarter valued at approximately $31,000. BNP Paribas Financial Markets raised its holdings in shares of Personalis by 406.4% during the second quarter. BNP Paribas Financial Markets now owns 6,451 shares of the company’s stock valued at $42,000 after acquiring an additional 5,177 shares during the period. Finally, Focus Partners Wealth acquired a new stake in shares of Personalis during the first quarter valued at approximately $47,000. Institutional investors and hedge funds own 61.91% of the company’s stock.

Analyst Ratings Changes

A number of research firms have commented on PSNL. Morgan Stanley dropped their price target on shares of Personalis from $10.00 to $9.00 and set an “equal weight” rating on the stock in a research report on Tuesday, May 12th. Wall Street Zen upgraded shares of Personalis from a “sell” rating to a “hold” rating in a report on Saturday, May 30th. Needham & Company LLC boosted their target price on shares of Personalis from $10.00 to $12.00 and gave the stock a “buy” rating in a report on Friday, February 27th. BTIG Research dropped their target price on shares of Personalis from $13.00 to $11.00 and set a “buy” rating on the stock in a report on Monday, May 11th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Personalis in a report on Tuesday, April 21st. Five investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $11.00.

Personalis Company Profile

Personalis, Inc (NASDAQ: PSNL) is a clinical‐stage genomics company that develops and markets advanced next‐generation sequencing (NGS) services and assays designed to accelerate precision medicine. The Company’s core offering is the ImmunoID NeXT™ Platform, which combines comprehensive tumor profiling—including whole exome, transcriptome, and T‐cell receptor sequencing—with proprietary bioinformatics to identify biomarkers and guide immuno‐oncology research. Personalis serves biopharmaceutical companies, academic institutions, and clinical research organizations seeking in‐depth insights into cancer, autoimmune diseases and other complex conditions.

In addition to its flagship ImmunoID NeXT™ Platform, Personalis offers a suite of customizable sequencing assays for biomarker discovery, clinical trial support and companion diagnostic development.